Dianthus Therapeutics (DNTH) Cash & Current Investments (2017 - 2025)

Dianthus Therapeutics' Cash & Current Investments history runs 9 years deep, the most recent figure standing at $403.5 million for Q4 2025.

• In Q4 2025, Cash & Current Investments rose 47.03% year-over-year to $403.5 million; the TTM figure through Dec 2025 stood at $403.5 million (up 47.03% YoY), while the FY2025 annual figure was $403.5 million, up 47.03% from the prior year.
• Cash & Current Investments was $403.5 million for Q4 2025 at Dianthus Therapeutics, roughly flat from $402.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $403.5 million in Q4 2025 to a low of $25.0 million in Q1 2023.
• Historically, Cash & Current Investments has averaged $212.5 million across 5 years, with a median of $191.2 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments tumbled 84.04% in 2023, then jumped 1408.63% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $176.9 million in 2021, then plunged by 57.33% to $75.5 million in 2022, then surged by 130.12% to $173.7 million in 2023, then jumped by 57.95% to $274.4 million in 2024, then soared by 47.03% to $403.5 million in 2025.
• The last three Cash & Current Investments figures came in at $403.5 million (Q4 2025), $402.6 million (Q3 2025), and $256.1 million (Q2 2025), per Business Quant data.